Abstract: A method, apparatus and system for detecting carbon emission-involved gas from a ruminant is provided, including: continuously receiving ear tag information of the ruminant in a monitoring range; determining an operation state of a feed supply system based on the ear tag information; and determining, based on collected emitted gas from the ruminant during eating, an emission rate of carbon emission-involved gas in the emitted gas when it is determined that the feed supply system is in a continuous operation state. In the method, apparatus and system, the ear tag information of the ruminant is detected to determine whether there is a ruminant in a detection area and feeding information of the ruminant, then the operation state of the feed supply system is controlled, and an intelligent information technology is used to acquire the emission rate of the carbon emission-involved gas matching the identity of the ruminant.

Abstract: A method for affecting operation of building equipment includes providing a plurality of reliability models that model failure probabilities of components of the building equipment as functions of equipment runtime, providing associations of the components with a plurality of subsystems of the building equipment, calculating, for the plurality of subsystems of the building equipment, probabilities of subsystem failure based on the reliability models for the components and the associations, and initiating an automated action to affect operation of the building equipment based on the probabilities of subsystem failure.

Abstract: Provided are compositions and methods for enhanced prime editing, which include a pegRNA that encodes a target mutation in a target protein, along with one or more nearby silent or conservative mutations. These silent mutations can increase the editing efficiency, without causing a change to the target protein sequence. Also provided are compositions and methods of using the improved prime editing for preventing or treating infections by SARS-CoV or SARS-CoV-2.

Abstract: The present invention relates to a tetracyclic derivative, a method for preparing same and the use thereof in medicine. In particular, the present invention relates to a tetracyclic derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof, and the use thereof as a therapeutic agent, especially as a K-Ras GTPase inhibitor, with definitions of each substituent in general formula (I) being the same as of which are defined in the description.

Abstract: A method for generating a reliability model, comprising receiving, by a processing circuit, historical operating data associated with one or more chillers or chiller components, the historical operating data including two or more event dates associated with the one or more chillers, calculating, by the processing circuit, a runtime of a chiller of the one or more chillers based on the two or more event dates, calibrating, by the processing circuit, the runtime by determining an idle time associated with the chiller corresponding to a location of the chiller and performing an operation using the runtime and the idle time to generate a calibrated runtime, and training, by the processing circuit, a chiller reliability model using the calibrated runtime to produce a trained model.

Abstract: The present invention relates to an alkyne derivative, a preparation method for same, and applications thereof in medicine. Specifically, the present invention relates to the alkyne derivative as represented by formula (I), the preparation method for same, a pharmaceutically acceptable salt thereof, and uses of them as a therapeutic agent, specifically as a phosphoinositide 3-kinase ? (PI3K?) inhibitor, where the definitions of the substituents in formula (I) are identical to the definitions in the description.

Abstract: A pyrazolo[1,5-a]pyridine derivative, and a preparation method and medical use thereof are provided. The pyrazolo[1,5-a]pyridine derivative shown in general formula (I), a preparation method of the derivative, a pharmaceutically acceptable salt of the derivative, and use of the derivative or salt as a therapeutic agent, especially as a rearranged during transfection (RET) inhibitor, are provided.

Abstract: A building system including one or more memory devices configured to store instructions thereon, that, when executed by one or more processors, cause the one or more processors to generate building recommendations based on recommendation requests with a model of a first model type when less than a predefined amount of model training data is available and receive feedback data on the recommendation requests generated by the model of the first model type. The instructions cause the one or more processors to transition from generating the building recommendations by the model of the first model type to a second model of a second model type by comparing performance of the first model type to the second model type based on the feedback data.

Abstract: A floor tile for an elevated floor in a building includes a non-through aperture defining a pocket within the floor tile having a base and one or more walls, an antenna disposed within the non-through aperture and configured to be communicably coupled to an access point, the antenna configured to transmit wireless signals, one or more reflective surfaces positioned on an inner surface of the non-through aperture and configured to reflect the wireless signals, and a shielding layer disposed on top of the antenna and configured to cover the non-through aperture to protect the antenna from an external environment.

Abstract: A method for preparing an itraconazole formulation including: dissolving a mixture of itraconazole and L-ascorbic acid with a mixed solvent of dichloromethane and methanol, adding a hydroxypropyl methylcellulose and a pluronic F-127 and then dichloromethane into the mixed solvent to obtain a raw material solution; feeding a carbon dioxide into a crystallization autoclave in a supercritical fluid crystallization equipment system through a pressure regulating valve; spraying the solution into the crystallization autoclave via a spray nozzle, separating out composite particles from the solution and collecting the composite particles at a bottom of the crystallization autoclave, and encapsulating the composite particles to obtain a itraconazole formulation with decreased particle size and increased bioavailability.

Abstract: A method for preparing an itraconazole formulation including: dissolving a mixture of itraconazole and L-ascorbic acid with a mixed solvent of dichloromethane and methanol, adding a hydroxypropyl methylcellulose and a pluronic F-127 and then dichloromethane into the mixed solvent to obtain a raw material solution; feeding a carbon dioxide into a crystallization autoclave in a supercritical fluid crystallization equipment system through a pressure regulating valve; spraying the solution into the crystallization autoclave via a spray nozzle, separating out composite particles from the solution and collecting the composite particles at a bottom of the crystallization autoclave, and encapsulating the composite particles to obtain a itraconazole formulation with decreased particle size and increased bioavailability.

Abstract: A device comprises a non-transitory memory having instructions and one or more processors in communication with the memory. The one or more processors execute the instructions to receive training data that represent dependent variable information from a plurality of cells in a cellular network. One or more clusters of cells are selected from the plurality of cells; while, one or more sub-clusters of cells are selected from the one or more clusters based on the dependent variable information. One or more models are determined corresponding to the one or more sub-clusters of cells based on the relationship between dependent variable information and independent variable information. A prediction value is output from the one or more models in response to the received testing data.

Abstract: A system and method of predicting cellular network performance based on observed performance indicator data from cells in the cellular network. The method includes accessing a set of observed performance indicator data, the performance indicator data including a time sequenced measure of performance indicators for the cellular network. The method then classifies the observed performance data based on a cell as one of a high load growth cell and a high load non-growth cell. Based on the classification of the cell, the method computes a future value of at least one performance indicator using a predictive model based on testing data for the cell in the observed performance indicator data. The predictive model is derived from training data in the observed performance indicator data. An indication of the future value of the at least one of the performance indicators is output when the future value exceeds an alarm value.